Venous thromboembolism is a very common complication of SCI (
4–
6). It is a cause of pulmonary embolism after SCI, which can ultimately cause death. The second edition of Clinical Practice Guidelines for thromboembolism prevention published in 1999 noted a 40% rate of DVT in patients with acute SCI (
6). A review article by Green noted the incidence of DVT to be 48 to 100% without anticoagulation prophylaxis and approximately 10% with prophylaxis (
4). The incidence of pulmonary embolism has been reported to be 2.6%, and it is the cause of death in 10% of individuals with SCI in the first year postinjury and in 3% after the first year (
4).
Venous thromboembolism in SCI is thought to be not only caused by venostasis but also due to a transient hypercoagulable state, reduced fibrinolytic activity, increased blood factor VIII activity, dehydration, and/or concomitant injury to the soft tissue or long bone (
6). In addition to SCI, other clinical risk factors for DVT are lower extremity fracture, previous thrombosis, cancer, heart failure, obesity, and age greater than 70 years, none of which this patient had prior to his SCI (
6). Another recent study by Jones and colleagues reported other risk factors for venous thromboembolism to include male gender, complete paraplegia compared with complete tetraplegia, and being African American (
7). Other significant comorbidities include metastatic cancer, underlying chronic neurological disease, history of psychiatric disease, and depression/anxiety. In this case, the significant risk factors were ethnicity, gender, and complete paraplegia.
There is a potential for DVT to progress proximally and to embolize in a high percentage of the cases (
6). However, routine use of prophylactic IVC filter does not seem to be indicated as a preventive measure against pulmonary embolism after SCI (
5,
8). Those patients with high risk factors, such as long bone fractures, DVT despite prophylactic anticoagulation, and contraindications to anticoagulation, may be appropriate candidates for prophylactic IVC filters (
4,
8). In this case, the patient had the last 2 indications for IVC filter placement, that is, he developed his initial DVT despite being on anticoagulation; then he developed hematoma at the surgical site and had a contraindication for anticoagulation at that time.
The term “phlegmasia cerulea dolens” (La phlebite bleue) was first used by Gregorie in 1938 when he described a condition that included venous thrombosis, painful ischemia, and purple discoloration (
1). Phlegmasia cerulea dolens is caused by complete occlusion of venous outflow from an extremity secondary to acute massive thrombosis, and it should include occlusion of both the major outflow channels and many of the collateral veins. This venous occlusion causes abnormally elevated intravascular hydrostatic pressure, which in turn causes massive extravasations of fluid into the surrounding tissue (
9). This extravasation leads to a decrease in arterial pressure. Combined with excessive interstitial hydrostatic pressure, the arterial closing pressure is exceeded, which collapses the arterial wall. These events ultimately cause tissue ischemia (
9). There is a subsequent loss of vascular volume, which can exceed 3 to 5 L and can result in hypotension, which was seen in this case. Signs and symptoms of PCD include intense pain, edema, decreased pulses, and a cyanotic, mottled extremity. It can be associated with a compartment syndrome, as seen in this case. Mortality from PCD has been reported in 20 to 40% of cases, and amputation has been performed in 12 to 50% of survivors (
1,
10–
12).
Goals of the treatment are to restore normal volume, prevent venous gangrene, and prevent pulmonary embolism (
9). Treatment of PCD remains controversial given its rarity. Immediate measures that could be taken are rapid volume replacement, extreme elevation of the extremity, and fasciotomies if compartment syndrome is present (
9). Other treatment options include sympathetic blockade, sympathectomy, venous surgical thrombectomy, catheter-directed thrombolysis, anticoagulation, and amputation (
1). In this case, anticoagulation and catheter-directed thrombolysis were attempted without success. Although there is very little literature on the subject of PCD, thrombectomy has been thought to be the most effective treatment option when it is initiated early (
1,
13). In 2 reported cases of PCD, a filter was placed via internal jugular vein to prevent pulmonary embolism from a subsequent thrombectomy (
3,
9).
This case illustrates a rare but potentially devastating complication of PCD with IVC filter placement. It is felt that there are 2 possible mechanisms for the development of PCD with IVC filter placement: thrombi propagate distally from the filter after the trapping of an embolus or proximally from the site of insertion of the filter in the femoral vein to the filter. Inferior vena cava filters have many other potential associated complications. These include bleeding or formation of thrombus at the site of insertion; perforation of the vena cava; and malposition or migration of the filter, including migration of the filter to the heart (
1,
2,
4,
14). One of the common long-term complications of IVC filters is caval thrombotic occlusion, which is reported to occur in 6 to 30% of cases (
5,
15,
16). Postphlebitic syndrome from chronic venous occlusion also has been reported with IVC (
5). Percutaneous IVC filter placement may prevent pulmonary embolism, but it does not affect the underlying thrombotic process and may contribute to thrombosis, as seen in this case (
5,
17).
In this patient, a retrievable Günther Tulip filter was placed. This has been used as a retrievable filter in Europe since 1992, and it has been approved by the United States Food and Drug Administration as a permanent filter since October 2000 and as a retrievable filter since October 2003 (
16,
18). It is a nonmagnetic conical-shaped filter with 4 main struts and 8 additional filter wires and a hook at the apex that is used in the retrieval process. This filter is 45-mm long and has an expanded diameter of 30 mm. It can be placed via the femoral or jugular approach, but it can only be retrieved from the jugular approach (
16). Like any other filter, the Günther Tulip filter causes a mild fibrotic reaction that eventually fixes the device to the endothelium. Allen reported only 1 complication in 53 cases, which was the inability to retrieve the filter (
18). Others reported complication rates of 3.6% for recurrent pulmonary embolism and 6% for total caval occlusion (
16). We are unaware of any report of PCD as a complication of a Günther Tulip IVC filter.